Quadria Capital-Led Consortium Eyes Majority Stake in Samarth Lifesciences at Rs 4,500 Cr Valuation
New Delhi: A consortium of private equity investors, led by healthcare-focused Quadria Capital, is assessing the acquisition of an 80-85% stake in Samarth Lifesciences in a potential deal that may value the company at around Rs 4,500 crore, with promoters seeking capital to accelerate expansion and scale operations.
The deal is currently under consideration, with several PE players evaluating the opportunity to acquire a controlling stake in the Mumbai-based pharmaceutical company, which has a strong presence in critical care therapies.
Following the transaction, the promoters are expected to retain a minority holding of about 15–20%, allowing them to stay involved in the company’s future growth. O3 Capital has been appointed as the advisor to manage the transaction process.
The company is looking to raise funds to support its next phase of growth, including expanding manufacturing capabilities and strengthening its footprint in the domestic pharma market.
Established in 1963, Samarth Lifesciences has developed a diversified product portfolio spanning key therapeutic areas such as critical care, cardiology, anti-infectives, urology, oncology, and gynaecology.
After remaining relatively under the radar for years, the company has drawn investor interest due to improved financial performance. It is estimated to have generated revenues of about ₹727 crore, growing at approximately 16%, with EBITDA in the range of ₹160–170 crore for FY26.
Earlier, global investors such as EQT, TPG, KKR, and Warburg Pincus had explored the deal but reportedly withdrew due to valuation disagreements with the promoters.
The promoters are said to be seeking a valuation of nearly 30 times earnings, which some investors view as aggressive, according to The Economic Times report.
Quadria Capital, headquartered in Singapore, manages over $4.2 billion in assets and has been actively investing in healthcare businesses across South and Southeast Asia, including several pharmaceutical ventures in India.
If the transaction goes through, it could emerge as one of the notable private equity deals in India’s pharmaceutical sector, reflecting sustained investor interest and consolidation trends in the industry.
